Statin use and risk of nonmelanoma skin cancer: a nationwide study in Denmark

S. Arnspang; A. Pottegård; Søren Friis; O. Clemmensen; K. E. Andersen; J. Hallas; D. Gaist

doi:10.1038/bjc.2014.527

Statin use and risk of nonmelanoma skin cancer: a nationwide study in Denmark

S. Arnspang, A. Pottegård, Søren Friis, O. Clemmensen, K. E. Andersen, J. Hallas, D. Gaist

10 Citations (Scopus)

Abstract

BACKGROUND: Evidence is conflicting regarding statin use and risk of basal cell (BCC) and squamous cell skin cancer (SCC).

METHODS: Using Danish nationwide registries, we identified all patients with incident BCC/SCC during 2005-2009 and matched them to population controls. We computed odds ratios (ORs) for BCC and SCC associated with statin use.

RESULTS: We identified 38,484 cases of BCC and 3724 cases of SCC. Statin ever use was associated with ORs of 1.09 (CI: 1.06-1.13) for BCC and 1.01 (CI: 0.91-1.11) for SCC.

CONCLUSIONS: Statin use was not associated with risk of SCC. Residual confounding plausibly explains the marginally increased risk of BCC.

Original language	English
Journal	B J C
Volume	112
Pages (from-to)	153-156
Number of pages	4
ISSN	0007-0920
DOIs	https://doi.org/10.1038/bjc.2014.527
Publication status	Published - 6 Jan 2015

Keywords

Adult
Aged
Aged, 80 and over
Case-Control Studies
Denmark
Female
Humans
Hydroxymethylglutaryl-CoA Reductase Inhibitors
Male
Middle Aged
Risk
Skin Neoplasms

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1038/bjc.2014.527Licence: CC BY-NC-SA

Cite this

@article{f607b9fb7c744b01bcb8f5cda4021284,

title = "Statin use and risk of nonmelanoma skin cancer: a nationwide study in Denmark",

abstract = "BACKGROUND: Evidence is conflicting regarding statin use and risk of basal cell (BCC) and squamous cell skin cancer (SCC).METHODS: Using Danish nationwide registries, we identified all patients with incident BCC/SCC during 2005-2009 and matched them to population controls. We computed odds ratios (ORs) for BCC and SCC associated with statin use.RESULTS: We identified 38,484 cases of BCC and 3724 cases of SCC. Statin ever use was associated with ORs of 1.09 (CI: 1.06-1.13) for BCC and 1.01 (CI: 0.91-1.11) for SCC.CONCLUSIONS: Statin use was not associated with risk of SCC. Residual confounding plausibly explains the marginally increased risk of BCC.",

keywords = "Adult, Aged, Aged, 80 and over, Case-Control Studies, Denmark, Female, Humans, Hydroxymethylglutaryl-CoA Reductase Inhibitors, Male, Middle Aged, Risk, Skin Neoplasms",

author = "S. Arnspang and A. Potteg{\aa}rd and S{\o}ren Friis and O. Clemmensen and Andersen, {K. E.} and J. Hallas and D. Gaist",

year = "2015",

month = jan,

day = "6",

doi = "10.1038/bjc.2014.527",

language = "English",

volume = "112",

pages = "153--156",

journal = "The British journal of cancer. Supplement",

issn = "0007-0920",

publisher = "nature publishing group",

}

TY - JOUR

T1 - Statin use and risk of nonmelanoma skin cancer

T2 - a nationwide study in Denmark

AU - Arnspang, S.

AU - Pottegård, A.

AU - Friis, Søren

AU - Clemmensen, O.

AU - Andersen, K. E.

AU - Hallas, J.

AU - Gaist, D.

PY - 2015/1/6

Y1 - 2015/1/6

N2 - BACKGROUND: Evidence is conflicting regarding statin use and risk of basal cell (BCC) and squamous cell skin cancer (SCC).METHODS: Using Danish nationwide registries, we identified all patients with incident BCC/SCC during 2005-2009 and matched them to population controls. We computed odds ratios (ORs) for BCC and SCC associated with statin use.RESULTS: We identified 38,484 cases of BCC and 3724 cases of SCC. Statin ever use was associated with ORs of 1.09 (CI: 1.06-1.13) for BCC and 1.01 (CI: 0.91-1.11) for SCC.CONCLUSIONS: Statin use was not associated with risk of SCC. Residual confounding plausibly explains the marginally increased risk of BCC.

AB - BACKGROUND: Evidence is conflicting regarding statin use and risk of basal cell (BCC) and squamous cell skin cancer (SCC).METHODS: Using Danish nationwide registries, we identified all patients with incident BCC/SCC during 2005-2009 and matched them to population controls. We computed odds ratios (ORs) for BCC and SCC associated with statin use.RESULTS: We identified 38,484 cases of BCC and 3724 cases of SCC. Statin ever use was associated with ORs of 1.09 (CI: 1.06-1.13) for BCC and 1.01 (CI: 0.91-1.11) for SCC.CONCLUSIONS: Statin use was not associated with risk of SCC. Residual confounding plausibly explains the marginally increased risk of BCC.

KW - Adult

KW - Aged

KW - Aged, 80 and over

KW - Case-Control Studies

KW - Denmark

KW - Female

KW - Humans

KW - Hydroxymethylglutaryl-CoA Reductase Inhibitors

KW - Male

KW - Middle Aged

KW - Risk

KW - Skin Neoplasms

U2 - 10.1038/bjc.2014.527

DO - 10.1038/bjc.2014.527

M3 - Letter

C2 - 25290087

SN - 0007-0920

VL - 112

SP - 153

EP - 156

JO - The British journal of cancer. Supplement

JF - The British journal of cancer. Supplement

ER -

Statin use and risk of nonmelanoma skin cancer: a nationwide study in Denmark

Abstract

Keywords

UN SDGs

Access to Document

Fingerprint

Cite this